Poseida Therapeutics Highlights Positive Interim Phase 1 Results for P-BCMA-ALLO1 and Preclinical Data for Dual CAR-T P-CD19CD20-ALLO1 at the 66th American Society of Hematology (ASH) Annual MeetingDecember 9, 2024
Poseida Therapeutics, Inc. Announces Agreement to be Acquired by Roche Holdings, Inc.November 26, 2024
Poseida Therapeutics Hosts Cell Therapy R&D Day Highlighting Its Innovative Clinical and Preclinical PipelineNovember 14, 2024
Poseida Therapeutics Provides Updates and Financial Results for the Third Quarter of 2024November 7, 2024
Poseida Therapeutics to Present Clinical and Preclinical Data on Investigational Allogeneic CAR-T Cell Therapies at SITC 2024 and ASH 2024November 5, 2024
Poseida Therapeutics to Present New Preclinical Data Supporting Non-Viral Gene Editing with P-KLKB1-101 for the Treatment of Hereditary AngioedemaOctober 24, 2024
Poseida Therapeutics Announces Nomination of New CAR-T Development Candidate Under Collaboration with RocheOctober 17, 2024
Poseida Therapeutics Named to Newsweek’s List of the Top 200 America’s Most Loved Workplaces for 2024October 3, 2024
Poseida Therapeutics Reports Positive Interim Phase 1 Results for Allogeneic CAR-T Therapy P-BCMA-ALLO1 with High Overall Response Rates in Heavily Pretreated Relapsed/Refractory Multiple Myeloma PatientsSeptember 27, 2024
Poseida Therapeutics Receives Regenerative Medicine Advanced Therapy (RMAT) Designation from FDA for P-BCMA-ALLO1 to Treat Relapsed/Refractory Multiple MyelomaSeptember 16, 2024
Poseida Therapeutics to Present New Clinical Data from Phase 1 Study of Allogeneic CAR-T P-BCMA-ALLO1 in Patients with Relapsed/Refractory Multiple Myeloma at 21st International Myeloma Society Annual MeetingSeptember 5, 2024
Poseida Therapeutics Presents New Case Study Demonstrating Reactivation of CAR-T Therapy with a T-Cell Engager in a Patient with Relapsed Multiple MyelomaSeptember 4, 2024
Poseida Therapeutics Provides Updates and Financial Results for the Second Quarter of 2024August 5, 2024
Poseida Therapeutics Provides Updates and Financial Results for the First Quarter of 2024May 14, 2024
Poseida Highlights Strong Progress on Its Genetic Medicine Programs at the American Society for Gene and Cell Therapy 27th Annual MeetingMay 9, 2024
Astellas and Poseida Therapeutics Enter Into Research Collaboration and License Agreement to Develop Novel Allogeneic Cell Therapies in OncologyMay 1, 2024
Poseida Therapeutics Announces Strong Lineup of Presentations at the American Society of Gene and Cell Therapy 27th Annual MeetingApril 18, 2024
Poseida Therapeutics Hosts Gene Therapy R&D Day Highlighting New Scientific Advancements and Pipeline FocusApril 17, 2024
Poseida Therapeutics Presents New Phase 1 Data at AACR 2024 Supporting Potential of P-BCMA-ALLO1 Allogeneic CAR-T Therapy to Benefit Broad Range of Patients with Multiple MyelomaApril 8, 2024
Poseida Therapeutics to Present at H.C. Wainwright 2nd Annual Cell Therapy Virtual ConferenceMarch 19, 2024
Poseida Therapeutics Announces FDA Orphan Drug Designation Granted to P-BCMA-ALLO1 for the Treatment of Multiple MyelomaMarch 13, 2024
Poseida Therapeutics Provides Updates and Financial Results for the Fourth Quarter and Full Year 2023March 7, 2024
Poseida Therapeutics Highlights Recent Progress, Strategic Priorities and Anticipated 2024 Key MilestonesJanuary 4, 2024
Poseida Therapeutics Presents Positive Early Results from its Phase 1 Trial of Allogeneic CAR-T P-BCMA-ALLO1 in Relapsed-Refractory Multiple Myeloma at the 65th American Society of Hematology (ASH) Annual MeetingDecember 10, 2023
Poseida Therapeutics Provides Updates and Financial Results for the Third Quarter of 2023November 9, 2023
Poseida Therapeutics Announces Strategic Investment by Astellas and Provides Business UpdateAugust 7, 2023
Astellas and Poseida Therapeutics Announce Strategic Investment to Support Poseida’s Commitment to Redefining Cancer Cell TherapyAugust 7, 2023
Poseida Therapeutics Announces FDA Clearance of Investigational New Drug Application for P-CD19CD20-ALLO1, an Allogeneic Dual CAR-T Cell Therapy for B-Cell MalignanciesJuly 5, 2023
Poseida Therapeutics to Present at 31st Congress of the International Society on Thrombosis and HaemostasisMay 22, 2023
Poseida Therapeutics Presents Encouraging Preclinical Data Across its Gene Therapy Programs at the American Society for Gene and Cell Therapy 2023 Annual MeetingMay 18, 2023
Poseida Therapeutics Announces Multiple Presentations at the American Society of Gene and Cell Therapy 26th Annual MeetingMay 2, 2023
Poseida Therapeutics Provides Updates and Financial Results for the Fourth Quarter and Full Year 2022March 9, 2023
Poseida Therapeutics Appoints Five New Members to Its Gene Therapy Scientific Advisory BoardMarch 1, 2023
Poseida Therapeutics Hosts Third Annual Virtual R&D Day Highlighting Novel Pipeline Assets and Latest Technology InnovationsFebruary 22, 2023
Poseida Therapeutics Presents Preclinical Data from P-FVIII-101 Gene Therapy for Hemophilia A at the 64th ASH Annual Meeting & ExpositionDecember 11, 2022
Poseida Therapeutics to Present Early Data from Phase 1 Trials of P-MUC1C-ALLO1 and P-BCMA-ALLO1 at ESMO Immuno-Oncology 2022 Annual CongressDecember 6, 2022
Poseida Therapeutics Provides Updates and Financial Results for the Third Quarter of 2022November 10, 2022
Poseida Therapeutics Provides Updates and Financial Results for the Third Quarter of 2022November 8, 2022
Poseida Therapeutics Announces Oral Presentation Highlighting P-FVIII-101 Gene Therapy at the 64th ASH Annual Meeting & ExpositionNovember 3, 2022
Poseida Therapeutics to Present Trial in Progress Poster for Phase 1 P-MUC1C-ALLO1 Study at the Society for Immunotherapy of Cancer Annual MeetingOctober 5, 2022
Poseida Therapeutics to Present at H.C. Wainwright 24th Annual Global Investment ConferenceSeptember 7, 2022
Poseida Therapeutics Provides Updates and Financial Results for the Second Quarter of 2022August 11, 2022
Poseida Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional SharesAugust 8, 2022
Poseida Therapeutics Announces Strategic Global Collaboration with Roche Focused on Allogeneic CAR-T Cell Therapies for Hematologic MalignanciesAugust 3, 2022
Renowned Geneticist to Chair Poseida Therapeutics Gene Therapy Scientific Advisory BoardJuly 26, 2022
Poseida Therapeutics Announces Publication Highlighting Potential of Cas-CLOVER™ as an Efficient and Robust Gene Editing System for Developing Allogeneic CAR-T ProductsJune 1, 2022
Poseida Therapeutics Presents Encouraging Preclinical Data Highlighting P-ckit-ALLO1 at the ASGCT 2022 Annual MeetingMay 17, 2022
Poseida Therapeutics Provides Updates and Financial Results for the First Quarter of 2022May 12, 2022
Poseida Therapeutics to Present at American Society of Gene and Cell Therapy 25th Annual MeetingMay 2, 2022
Poseida Therapeutics Provides Updates and Financial Results for the Fourth Quarter and Full Year 2021March 10, 2022
Poseida Therapeutics Hosts Second Annual Virtual R&D Day Highlighting Novel Pipeline Assets and Latest Technology InnovationsFebruary 23, 2022
Poseida Therapeutics to Present Interim Results from Phase 1 Trial of P-PSMA-101 at ASCO Genitourinary Cancers SymposiumFebruary 17, 2022
Poseida Therapeutics Announces Eric Ostertag to Serve as Executive Chairman and Transition Role of CEO to Current President and CBO Mark GergenJanuary 10, 2022
Poseida Therapeutics Announces FDA Clearance of Investigational New Drug Application for P-MUC1C-ALLO1, a Fully Allogeneic CAR-T Targeting Multiple Solid TumorsDecember 20, 2021
Poseida Therapeutics Provides Update on BCMA-Targeted CAR-T Clinical Trials at the 2021 American Society of Hematology (ASH) Annual MeetingDecember 13, 2021
Poseida Therapeutics to Present Preclinical Data Highlighting Fully Allogeneic CAR-T Product Candidates at the Society for Immunotherapy of Cancer 2021 Annual MeetingNovember 9, 2021
Poseida Therapeutics Provides Program Updates and Financial Results for the Third Quarter of 2021November 9, 2021
Poseida Therapeutics Announces Research Collaboration with Takeda for Novel Non-Viral In Vivo Gene TherapiesOctober 12, 2021
Poseida Therapeutics to Present at Society for Immunotherapy of Cancer 2021 Annual MeetingOctober 1, 2021
Poseida Therapeutics Reports Program Updates and Financial Results for the Second Quarter of 2021August 12, 2021
Poseida Therapeutics Presents Preliminary Results from Phase 1 Trial of P-PSMA-101 at the 6th Annual CAR-TCR SummitAugust 3, 2021
Poseida Therapeutics Announces FDA Clearance of Investigational New Drug Application for P-BCMA-ALLO1, an Allogeneic CAR-T Candidate for Relapsed/Refractory Multiple MyelomaAugust 2, 2021
Poseida Therapeutics Presents Encouraging Preclinical Data Across its CAR-T and Gene Therapy Programs at the American Society of Gene and Cell Therapy 2021 Virtual Annual MeetingMay 11, 2021
Poseida Therapeutics Reports Program Updates and Financial Results for the First Quarter 2021May 11, 2021
Poseida Therapeutics to Present at American Society of Gene and Cell Therapy 2021 Annual MeetingApril 27, 2021
Poseida Therapeutics Announces Carl June, M.D., to Chair Immuno-Oncology Scientific Advisory BoardMarch 23, 2021
Poseida Therapeutics Reports Program Updates and Financial Results for the Fourth Quarter and Full Year 2020March 11, 2021
Poseida Therapeutics Provides Update on Key Programs and Developments During R&D DayFebruary 24, 2021
Poseida Therapeutics Provides Update on Phase 1 Trial of P-BCMA-101 at the 2020 American Society of Hematology Annual MeetingDecember 5, 2020
Poseida Therapeutics Reports Operational Update and Financial Results for Third Quarter 2020November 12, 2020
Poseida Therapeutics Announces Clinical Hold Lifted on Phase I Autologous CAR-T Study in Prostate CancerNovember 2, 2020
Poseida Therapeutics and TScan Therapeutics Announce Research Collaboration and License Agreement to Explore Developing Allogeneic T Cell Receptor Therapies for the Treatment of COVID-19October 21, 2020
Poseida Therapeutics to Present CAR-T Manufacturing Process Optimization Data at CAR-TCR Digital Week 2020September 16, 2020
Poseida Therapeutics Reports Operational Update and Financial Results for Second Quarter and First Half of 2020August 20, 2020
Poseida Therapeutics Announces Dosing of First Patient in Phase 1 Clinical Trial of P-PSMA-101 Autologous CAR-T for Metastatic Castration-Resistant Prostate CancerMay 20, 2020
Poseida Therapeutics to Present Update on Approach in Allogeneic CAR-T at Society for Immunotherapy of Cancer 34th Annual MeetingNovember 5, 2019
Poseida Therapeutics to Provide Update on Phase 1 Study of P-BCMA-101 at the 2018 American Society of Hematology Annual MeetingNovember 1, 2019
Poseida Therapeutics’ Clinical Update of BCMA-specific CAR-T Program Selected as a Late Breaking Presentation at the 4th Annual CAR-TCR Summit 2018August 1, 2019
Poseida Therapeutics Receives US FDA Orphan Drug Designation for P-BCMA-101 for the Treatment of Multiple MyelomaMay 13, 2019
Poseida Therapeutics Announces Notice of Allowance for New Patents and Registration of New TrademarksFebruary 13, 2019
Poseida Therapeutics Appoints Two Independent Directors, Adding Leaders for Compensation and Governance FunctionsJanuary 4, 2019
Poseida Therapeutics Provides Update on Phase 1 Study of P-BCMA-101 CAR-T Product Candidate at the 2018 American Society of Hematology Annual MeetingDecember 3, 2018
Poseida Therapeutics Receives Regenerative Medicine Advanced Therapy (RMAT) Designation from FDA for P-BCMA-101November 5, 2018
Poseida Provides Update on Phase 1 Study of P-BCMA-101 CAR-T Stem Cell Memory Product in Patients with Relapsed/Refractory Multiple MyelomaSeptember 5, 2018
Teneobio and Poseida Expand Their Partnership to Develop UniDabs™ for Advanced CAR-T TherapiesAugust 7, 2018
Poseida Awarded $3.99 Million CIRM Grant to Support Preclinical Development of P-PSMA-101, a T Stem Cell Memory CAR-T Therapy for Prostate CancerJuly 20, 2018
Poseida Therapeutics Presents Clinical Manufacturing Method for Durable, Persistent CAR-T Stem Cell Memory Therapies at World Orphan Drug Congress USAApril 26, 2018
Poseida Announces Initial Phase 1 Data for P-BCMA-101 CAR-T Stem Cell Memory Product in Patients with Relapsed/Refractory Multiple MyelomaApril 17, 2018
Poseida to Present P-BCMA-101 Phase 1 Data at the American Association for Cancer Research (AACR) Annual Meeting 2018March 26, 2018
Poseida Therapeutics Appoints Mark Gergen as Chief Business Officer and Chief Financial OfficerFebruary 28, 2018
Poseida Therapeutics Presents Stem Cell Memory CAR-T Therapy for Prostate Cancer at 2018 Keystone Symposia on Emerging Cellular TherapiesFebruary 14, 2018
Poseida Therapeutics Appoints Martin Giedlin, Ph.D., as Vice President, Technical OperationsFebruary 5, 2018
Poseida Therapeutics Announces First Patient Treated in Phase 1 Study of P-BCMA-101 CAR-T Stem Cell Memory Therapy in Patients with Multiple MyelomaDecember 18, 2017
Multiple Programs Featuring Poseida Therapeutics’ Advanced CAR-T Therapies Presented at American Society of Hematology 2017 Annual MeetingDecember 11, 2017
Poseida Therapeutics Presents Preclinical Solid Tumor Data for P-PSMA-101 at the American Association for Cancer Research Prostate Cancer MeetingDecember 1, 2017
Poseida Therapeutics Presents on the Development of Allogeneic and Autologous BCMA-Specific CAR-T Therapies at Precision: Blood Cancer SummitNovember 14, 2017
Poseida Therapeutics to Present anti-PSMA CAR-T Preclinical Data at the Society for Immunotherapy of Cancer (SITC) 32nd Annual MeetingNovember 8, 2017
Poseida Awarded $19.8 Million CIRM Grant to Support Clinical Trial of P-BCMA-101, a T Stem Cell Memory CAR-T Therapy for Multiple MyelomaOctober 26, 2017
Poseida Therapeutics Presents Preclinical Solid Tumor Data for P-PSMA-101, a CAR-T Therapy Predominantly Comprised of Stem Cell Memory T Cells, at the Prostate Cancer Foundation Annual RetreatOctober 5, 2017
Poseida Therapeutics Opens Enrollment in a Phase 1 Study of BCMA-Specific CAR-T Stem Cell Memory Therapy for Patients with Multiple MyelomaSeptember 26, 2017
Poseida Therapeutics Presents High-Fidelity Genome Editing System for Production of Allogeneic “Universal Donor” CAR-T Cells at American Society of Clinical Oncology Annual MeetingJune 5, 2017
Teneobio and Poseida Announce License Agreement for the Use of UniDab™ in CAR T-Cell TherapyMay 22, 2017
Poseida Therapeutics Presents Preclinical Data Demonstrating Multiple Therapeutic Advantages from BCMA-Specific CAR-T Program at American Association for Cancer Research Annual MeetingApril 4, 2017
Poseida Therapeutics Presents Preclinical Data Demonstrating Tumor Response from BCMA-Specific CAR-T Program at American Society of Hematology Annual MeetingDecember 5, 2016
Poseida Therapeutics to Present Three Abstracts on Novel BCMA-Specific CAR-T Therapy at American Society of Hematology 2016 Annual MeetingNovember 3, 2016
Poseida Therapeutics, Inc. Announces Worldwide License Agreement With Janssen to Apply Centyrin Technology in the Development of Chimeric Antigen Receptor (CAR) TherapiesAugust 11, 2015
Poseida Therapeutics, Inc., Expands Into JLABS to Foster Research Collaboration With Janssen for Development of Allogeneic CAR-T TherapiesJune 1, 2015
